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Abstract 
 
Background: Children with cancer are a unique patient population with high-resource, 
complex health care needs. Understanding their healthcare utilization could highlight 
areas for care optimization. 
 
Procedure: We performed a retrospective, cross-sectional analysis of the 2014 Truven 
Marketscan Medicaid Database to explore clinical attributes, utilization, and spending 
among children with cancer who were Medicaid enrollees. Eligible patients included 
children (ages 0-18 years) with cancer (Clinical Risk Group 8). Healthcare utilization and 
spending (per-member-per-month) were assessed overall and across specific health care 
services. 
 
Results: Children with cancer (n=5,405) represent less than 1% of the 1,516,457 children 
with medical complexity in the dataset. Children with cancer had high services use: 
laboratory/radiographic testing (93.0%), outpatient specialty care (83.4%), outpatient 
therapy/treatment (53.4%), emergency department (43.7%), hospitalization (31.5%), 
home health care (9.5%). Per-member-per-month spending for children with cancer was 
$3,706 overall and $2,323 for hospital care. 
 
Conclusion: Children with cancer have high healthcare resource use and spending. 
Differences in geographic distribution of services for children with cancer and the 
trajectory of spending over the course of therapy are areas for future investigation aimed 
at lowering costs of care without compromising on health outcomes. 
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Background 
Children with cancer represent a unique patient population with high resource, complex 
health care needs.1-5 Prior to diagnosis, these children may interact minimally with the 
healthcare system; upon diagnosis, their needs dramatically change. However, little 
research has been devoted to understanding healthcare utilization in this population. 
Children with cancer, often excluded from analyses in prior studies of children with 
medical complexity (CMC), are a novel population with healthcare utlization that 
warrants further study. 
 
Children with cancer have the potential to experience a wide range of life-threatening 
complications from their cancer or associated therapy.6-9 For example, fever and 
neutropenia (FN) is a common complication of cancer therapy that requires timely 
evaluation7,10-12 in the emergency department (ED) or outpatient center, with high rates of 
admission.1,2 Rapid access to acute care and supportive treatments received within the 
healthcare system are likely integral to the improved survival of this population.13 
 
As with other CMC, the majority of pediatric oncology care is provided at urban, tertiary 
care centers, but patients are spread geographically. This may lead families to seek ED 
care and outpatient care at local facilities that do not possess the specialty services of the 
institutions where children receive their cancer treatment. Payor claims data, such as 
Medicaid, that include both community and tertiary care facility information not available 
in other large datasets, may allow for a comprehensive assessment of care received by 
children with cancer. In the United States, children can be enrolled on Medicaid if their 
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family’s income meets the state determined poverty line or they can be enrolled on 
Children’s Health Insurance Program which covers uninsured children in families with 
incomes that are modest but too high to qualify for Medicaid.14 In some states, children 
with cancer may qualify for Medicaid if they meet criteria for disability or by the loss of 
income or resources due to the financial burden on families of children with cancer.15,16 
 
Previous analyses of Medicaid data have revealed that among all children, those with 
medical complexity account for half of Medicaid’s spending on hospital care.17 Yet, 
detailed healthcare utilization of children with cancer has not yet been explored. The 
objectives of this study are to 1) describe the clinical attributes of children with cancer 
who are covered by Medicaid, 2) evaluate their healthcare utilization and spending and 3) 
compare the distribution of utilization and spending by type of cancer.  
 
Methods 
Study Design and Setting 
We performed a retrospective, cross-sectional analysis of the Truven Marketscan® 
Medicaid Database (Ann Arbor, MI). The Marketscan® Medicaid Database includes 
complete paid medical and prescription drug claims from ten states. Truven maintains 
data validity and integrity through audits conducted to assess and remove invalid 
diagnosis and procedure codes. The Indiana University IRB determined this study is 
exempt from review due to de-identified data status. There were 6,792,909 children ages 
0-18 years enrolled in Medicaid in the year 2014 residing in 10 de-identified states from 
the database representing all geographic regions of the U.S.  
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Study Population/Identification of Cases 
 
The Clinical Risk Group (CRG) software v.1.3 (3M Health Information Systems) was 
used to assign each Medicaid recipient to a single, mutually exclusive CRG based on the 
individual’s diagnoses and health services utilization over a period of time.18-21 We used 
the CRG classification to select the population of interest: children with cancer (CRG 8; 
all malignancies). We used three years of claims data to properly assign CRG 
categories.22,23  
 
Outcome and Exploratory Variables 
The main outcomes of interest were healthcare utilization and spending. We assessed the 
outcomes overall and by specific health services, including: emergency department, home 
health/durable medical equipment, inpatient, outpatient laboratory testing, pharmacy 
(outpatient only), primary care, specialty care (including all outpatient specialty care), 
therapy/treatment (including procedures, physical, occupational, and all outpatient 
therapies), mental health/substance abuse (all professional and facility claims), and 
dental. Of note, emergency department charges are included within inpatient charges for 
those patients admitted from the ED. Spending was the payment made by Medicaid for 
each health service. We evaluated healthcare spending in the following ways: overall per 
year, per-member-per-month (PMPM) spend (calculated by summing the specific spend 
of a population over a year, dividing by 12, then dividing by the number of enrollees in 
the population), and by specific health services. We chose to evaluate PMPM spending 
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since not all patients in this cohort were enrolled on Medicaid for the entire 12 months 
evaluated. PMPM spending is a standard metric used by payors to track utilization since 
insurance enrollment is on monthly basis.  
 
We assessed the types of the children’s cancer using 3M’s CRG Episode Disease 
Category (EDC) for acute lymphoblastic leukemia (ALL), acute myelogenous leukemia 
(AML), central nervous system tumors (CNS), solid tumors (non-CNS), Hodgkin 
lymphoma, and non-Hodgkin lymphoma. Patients with non-specified malignancies, more 
than one type of cancer, or rare cancers were placed into an “Other” category.  
 
Demographic characteristics included age, gender, race/ethnicity (White, Non-Hispanic; 
Black, Non-Hispanic; Hispanic; and Other), and eligibility type (blind/disabled, other).  
 
Statistical Analyses 
We summarized patient and encounter characteristics using frequencies and percentages. 
We also evaluated healthcare utilization and spending - overall and by specific health 
services. We then stratified the healthcare utilization analyses by type of cancer. Analyses 
were performed on enrollees from all 10 states in the database using SAS version 9.3 
(SAS Institute, Cary, North Carolina).  
 
Results 
Study Population Characteristics 
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In 2014, there were 5,905 children with cancer identified in the 10 states participating in 
the Marketscan Medicaid database, which accounted for 0.2% of all patients in the 
dataset. Children with medical complexity (CMC) comprised 22.3% (N=1,516,457) of 
the Medicaid population in the dataset, and therefore children with cancer were 0.3% of 
CMC. The mean age of the children with cancer enrolled in Medicaid was 11.2 years 
(Table 1). About 40% of the children with cancer who were Medicaid enrollees were 
eligible due to disability or blindness. Regarding types of cancer, 27.2% of children had 
ALL, 26.8% had a non-CNS solid tumor, 24.7% had a CNS tumor, 2.6% had AML, 1.0% 
had Non-Hodgkin lymphoma, 0.4% had Hodgkin lymphoma, and 16.7% were 
categorized as “other” cancer type.  
 
Health Services Utilization and Spending  
Figure 1 demonstrates the percent of the population that utilized each service type, 
percent of spend, and PMPM spending on each of the types of healthcare services for 
children with cancer. We found that 31.5% of children with cancer utilized inpatient care 
For patients who utilized inpatient care over the one-year studied, children with cancer 
had a median inpatient stay of 10 days (range 4-28). Children with cancer used the 
following services: laboratory and radiographic testing (93.0%), outpatient specialty care 
(83.4%), outpatient therapy/treatment (53.4%), emergency care (43.7%), and home health 
care (9.5%).  
 
The overall per-member/per-month (PMPM) spending was $3,706 for children with 
cancer, with the majority (62.7%) spent on inpatient hospital care ($2,323) and 
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medications ($504). Conversely, children with cancer had a low percent of spending on 
outpatient specialty care (3.5%).  
 
Comparing Health Service Spending by Type of Cancer 
When evaluating the percent of spending and PMPM within each type of cancer, those 
with Non-Hodgkin lymphoma had the highest total PMPM spending ($4,999) and the 
highest percent (77.7%) of total spending on inpatient hospital care (PMPM $3,883) 
(Table 2). Children with ALL and AML had similar PMPM spending on medications 
(ALL $351 vs AML $352). Children with ALL had the highest percent spending for 
medications (18.2%) and outpatient therapy/treatment (10.6%, PMPM $205). Patients 
with Hodgkin lymphoma had the highest percent of their spending on laboratory and 
radiographic testing (17.0%), but patient’s with CNS tumors had the highest PMPM on 
testing ($236).  
 
Discussion 
Within this multi-state Medicaid population analysis, we documented spending patterns 
for children with cancer. We revealed that the greatest amount of spending by children 
with cancer was on inpatient services and the highest spending PMPM was for children 
with Non-Hodgkin lymphoma. Further investigation is needed to characterize fully all 
children with cancer who receive Medicaid coverage, as some of these patients may have 
been prior Medicaid recipients, some may have enrolled at diagnosis, and others may 
obtain coverage after loss of private health insurance due to financial stressors of 
caregivers. Future research efforts could also focus on further evaluation of inpatient care 
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costs to potentially identify novel cost-effectiveness strategies for those conditions that 
are not life-threatening, but contribute substantially to the financial burden of care.   
 
When evaluating the health care utilization patterns of children with cancer, several 
interesting findings were revealed. The high inpatient utilization (31.5%) demonstrates 
that children with cancer have high inpatient care needs, likely due to admissions for 
scheduled chemotherapy combined with the management of sequelae related to their 
disease and treatment. The use of outpatient therapy/treatment is consistent with clinical 
expectations since the majority of oncology therapy includes the infusion of 
chemotherapy in the outpatient setting and procedures (such as lumbar punctures for the 
administration of intrathecal chemotherapy). Lab and imaging studies, in conjunction 
with clinical exam findings, are clinically necessary to stage disease, monitor response to 
treatment (i.e. achieving remission and monitoring for disease recurrence), and screen for 
chemotherapy side effects. The utilization of home health care by children with cancer is 
likely explained by the need for home administration of intravenous or subcutaneous 
chemotherapy or supportive medications (such as granulocyte colony stimulating factor 
injections). The majority of children with cancer have a central line that requires 
maintenance by the caregivers in the home with education on care provided by home 
health nursing. Further, patients may utilize home health care for supportive care 
measures such as drawing labs in between clinic visits and intravenous fluid 
administration during times of poor oral intake due to chemotherapy induced nausea and 
vomiting.  
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When evaluating the PMPM spending by children with cancer, the largest amount of 
spending was for inpatient hospital care, followed by medications. There is a wide range 
of reasons children with cancer require inpatient hospital care including the 
administration of chemotherapy and the management of cancer related or therapy induced 
complications, such as fever and neutropenia (FN). FN is a common reason for admission 
among children with cancer,3,4 but there is evidence to suggest that we could reduce or 
shorten the length of inpatient stays for low-risk patients.24 It is imperative to take the 
financial impact of outpatient therapy for FN into account, especially for those patients 
and families with limited resources (including financial and travel). Transitioning the 
inpatient management of FN to outpatient care might require that patients visit the clinic 
several days in a row for reassessment, which can be especially difficult for those who 
live far away from their treating institution, especially if the cost of travel or lodging 
would be out of pocket.  
 
ED utilization by children with cancer was higher (43.7%) than the general pediatric 
population with Medicaid coverage during 2014 (22.9%).25 This high utilization of the 
ED would suggest that future research efforts are needed to understand better the reasons 
for ED visits and frequency of admissions, as well as the patient experience of these 
populations related to their acute care needs. This knowledge will allow for the design of 
interventions to improve ED care for this population in a meaningful way. It will be 
important to determine variations in care of this high needs population, either between the 
care received at a community ED versus a tertiary care institution or even between 
different tertiary care institutions. These investigations could lead to an improvement in 
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the quality of care and health outcomes for children with cancer who have acute care 
needs. 
 
When we evaluated spending by type of cancer, patients with a diagnosis of NHL had the 
highest overall spending, likely reflecting high inpatient hospital care usage. Patients with 
certain types of Non-Hodgkin lymphoma, including Burkitt lymphoma, are at very high 
risk for tumor lysis syndrome at diagnosis, and some of the high costs may be related to 
expensive medications used to treat tumor lysis (i.e. rasburicase), intensive care unit 
requirements for the management of complications, and length of hospital stays when 
these complications occur.8 Further studies exploring patient-level hospital records could 
elucidate a more detailed explanation for such high spending by this population. 
Furthermore, future research endeavors could focus on the trajectory of care for children 
with cancer to understand their patterns of healthcare utilization throughout the course of 
their therapy. Patients with Hodgkin lymphoma had the highest percent of their spending 
on laboratory and radiographic testing, which is expected given that their disease status is 
monitored closely using imaging studies, such as CT scans and PET-CT scans.26 Children 
with CNS tumors had the highest PMPM spending on laboratory and radiographic 
testing, likely due to the higher costs of MRIs, which are the preferred imaging modality 
to assess brain tumors.  
 
Whether children are enrolled on Medicaid simply because of a qualifying diagnosis of 
cancer or due to family financial constraints is not completely clear. We found that a 
large proportion of children with cancer are eligible due to disability/blindness (40.4%). 
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Yet, there is literature to support that the financial burden of a diagnosis of childhood 
cancer is substantial.16 It is possible that novel interventions among the Medicaid patient 
population could help offset some of the inpatient costs, while making outpatient 
management more feasible for patients and their families who have low resources. If 
Medicaid paid for lodging and food for those patients who travel long distances for their 
oncology care, transitioning inpatient care to outpatient care might result in lower total 
costs to the healthcare system and to the families of children with cancer. Hospitals and 
insurance companies may benefit from delving further into the financial status and 
constraints faced by the population of children with cancer within their facilities or under 
their coverage to reveal methods in which cost-savings might be achieved through 
alternatives to hospitalization.  
 
Our analysis of spending and healthcare utilization by children with cancer enrolled on 
Medicaid does not have direct correlations with the quality of care or outcomes 
associated with Medicaid coverage. Yet, recent calls to action for improvements in the 
care of children with cancer in low- to middle-income countries includes enhancing 
financial coverage of childhood cancer treatment.27 As more countries, such as Mexico,28-
30 are initiating and adjusting their financial coverage for childhood malignancies, the 
Medicaid model of continual payment for care throughout the trajectory of treatment 
could serve as a role model.  
 
Limitations 
Medicaid Pediatric Cancer Healthcare Spending     13 
There are several important limitations of this study. We included all patients enrolled on 
Medicaid within the dataset who had visits associated with a diagnosis of cancer, but 
were not able to capture the spending trajectory for these patients from the date of 
diagnosis through treatment. We were also not able to differentiate the reasons for 
inpatient hospital care or outpatient services, such as whether the visits were routine 
follow-up versus sick visits. Also, ED utilization may be underestimated as the charges 
for ED visits are included within inpatient charges for those patients admitted from the 
ED. The Truven dataset contains information from 10 states; therefore our analysis may 
not represent the healthcare utilization of all children throughout the United States and 
may not be generalizable to systems of healthcare delivery outside of the United States. 
The healthcare utilization by children with cancer enrolled on Medicaid may not be 
generalizable to those with private or no health insurance. Yet, the clinical scenarios are 
typically similar regardless of the patient’s insurance status and therefore some of the 
overarching findings may hold true, such as the large spending occurring on inpatient 
services. It is also important to point out that the administrative nature of this database 
encompasses costs and health services utilized, but does not indicate health outcomes or 
quality of care. While the de-identified nature of the dataset does not allow us to 
determine in which 10 states the patients resided and received care, it is likely that many 
of these states have similarities in the fact that pediatric oncology care is provided in only 
a few urban settings to patients who are geographically dispersed throughout the state.  
 
Conclusion 
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In summary, children with cancer have high health care utilization, especially inpatient 
hospital care. Healthcare systems and health insurance providers, including Medicaid, 
could benefit from performing a more detailed analysis of children with cancer within 
their systems and considering novel interventions to offset inpatient hospital care costs. 
Future studies that combine data from a variety of sources to obtain a complete picture of 
health care utilization, including an understanding of the geographical scope of care 
provided to children with cancer, combined with clinical outcomes, would be useful in 
determining current patterns of care delivery for this unique population and its impact on 
health outcomes.  
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Figure Legend 
 
Figure 1. Health Care Utilization and Spending for Children with Cancer in Medicaid  
 
TABLE 1. Demographics and Characteristics of Children in Medicaid, Both Overall and 
for Children with Cancer to Children 
 
 Overall 
N=1,516,457 
Cancer 
N=5,905 
 N (%) 
Age (years): Mean (95% CI)  10.7 (10.7-10.7) 11.2 (11.1-11.4) 
  0-4 274,176 (18.1) 842 (14.3) 
  5-9 395,562 (26.1) 1,622 (27.5) 
  10-14 388,434 (25.6) 1,482 (25.1) 
  15-18 458,285 (30.2) 1,959 (33.2) 
Gender   
  Male 825,647 (54.4) 3,129 (53) 
  Female 690,810 (45.6) 2,776 (47) 
Race   
  White 708,226 (46.7) 2,826 (47.9) 
  Black   504,540 (33.3) 1,081 (18.3) 
  Hispanic 107,074 (7.1) 452 (7.7) 
  Other 196,617 (13) 1,546 (26.2) 
Basis of Eligibility   
  Due to disability/blind 146,523 (9.7) 2,386 (40.4) 
  Other 1,369,934 (90.3) 3,519 (59.6) 
Enrollment Months: Mean (95% 
CI) 
11.3 (11.3-11.3) 11.1 (11.0-11.1) 
 
 
    
TABLE 2. Percentage of Total Expenditures for Top 5 Services for Children with Cancer on Medicaid, by Type of Cancer 
 
Total No. = 5,905 ALL Solid tumor, 
non-CNS 
CNS AML Non-Hodgkin 
Lymphoma 
Hodgkin 
Lymphoma 
No. (%) 1,609 (27.2%) 1,585 (26.8%) 1,458 (24.7%) 153 (2.6%) 60 (1.0%) 26 (0.4%) 
Type of Service % 
Spend 
PMPM % 
Spend 
PMPM % 
Spend 
PMPM % 
Spend 
PMPM % 
Spend 
PMPM % 
Spend 
PMPM 
Total  $1,930  $2,946  $2,614  $2,862  $4,999  $1,118 
Hospital Care 52.3 $1,010 67.2 $1,980 51.8 $1,354 69.5 $1,990 77.7 $3,883 48.4 $541 
Medications 18.2 $351 9.0 $266 15.8 $414 12.3 $352 8.9 $443 10.7 $120 
Outpatient 
therapy/treatment 10.6 $205 4.9 $145 6.8 $178 4.3 $124 2.3 $114 8.4 $94 
Laboratory and 
radiographic 
testing 
4.3 $84 7.8 $231 9.0 $236 4.4 $125 4.5 $224 17.0 $190 
Outpatient 
specialty care 4.0 $77 4.0 $119 6.0 $157 2.9 $82 2.7 $136 2.0 $22 
Top 5 services were based on overall trends among children with cancer 
Bolded indicates highest percentage of total expenditure or highest per-member-per-month (PMPM) spending per type of service 
ALL=Acute lymphocytic leukemia, CNS=Central nervous system, AML=Acute myelogenous leukemia 
  

